



Relburn-Metabolomics, Inc.
Westfield, NJ 07090

Relburn-Metabolomics Announces a Second Drug Development Program in a Highly Prevalent Liver Disease

Company to Present at NJ BIO Partnering Conference on May 23, 2017

Westfield, NJ – May 19, 2017 -- Relburn-Metabolomics, Inc. announced that the Company will review plans for development of a new drug in a second indication, nonalcoholic steatohepatitis (NASH), in addition to the previously announced gout program.

NASH occurs as a consequence of fat accumulation in the liver. So-call “fatty liver” affects up to 30% of the U.S. population. In many patients, the excess fat has no adverse consequences; however, in about 20% of patients, an inflammatory process is triggered which can progress into NASH. Over time, NASH can lead to liver fibrosis and cirrhosis, which can require liver transplantation. The nature of this inflammatory trigger is uncertain, but at least 50% of NASH patients also develop elevated uric acid, the target of the Relburn compounds. A number of experts have proposed that this metabolic process may be causative for NASH in this patient subgroup. Relburn compounds inhibit metabolic processes that increase uric acid, and this inhibition has been proposed as both prevention and treatment in NASH.

No drugs have yet been approved for treatment of NASH. Relburn expects to introduce a separate discrete compound for its NASH program with a target profile different from its gout program. These findings will be discussed by the Company’s Chief Executive Officer, Dr. Raymond P. Warrell, Jr., at the BIO NJ Partnering Conference at Rutgers University, Piscataway, NJ on May 23, 2017 at 2:30PM.

About Relburn-Metabolomics

Relburn is an emerging life-science company focused on improving health for patients with metabolic and inflammatory diseases. Relburn’s lead programs include transformational therapy for chronic gout and NASH, diseases that afflict 16 million patients each in the US/EU and are equally epidemic in Asia. Targeting enzymes that regulate both production and excretion of uric acid, Relburn compounds are markedly more potent than standard monofunctional drugs and have demonstrated exceptional clinical activity. Relburn believes its drugs may replace current 1st-line treatments for gout, thereby leading to meaningful improvements in patient well-being. Successful

development in NASH can markedly improve patient well-being and relive both morbidity and mortality from this progressive disease that lacks any current therapy. Further information can be accessed at: www.relburn.com.

Relburn company information: info@relburn.com

SOURCE: Relburn-Metabolomics® Inc.